{"transactions":[{"id":4097,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":160000,"derivative":{"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001781450-26-000002","document":"form4-09042026_060904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781450/000178145026000002/form4-09042026_060904.xml","form_type":"4"}},{"id":4096,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":320000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001781450-26-000002","document":"form4-09042026_060904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781450/000178145026000002/form4-09042026_060904.xml","form_type":"4"}},{"id":960132,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-12-23T12:25:58.000Z","date":"2025-12-19","kind":"purchase","planned":false,"acquired":true,"shares":56000,"price":1.81,"value":101360.0,"ownership":{"direct":true},"balance_after":188516,"source":{"system":"sec-edgar","filing":"0001781450-25-000005","document":"form4-12232025_121255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000178145025000005/form4-12232025_121255.xml","form_type":"4"}},{"id":1048602,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-04T21:00:10.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":340000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":340000},"source":{"system":"sec-edgar","filing":"0001415889-25-023700","document":"form4-09042025_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023700/form4-09042025_050901.xml","form_type":"4"}},{"id":1048601,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-09-04T21:00:10.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":195000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":2344418,"source":{"system":"sec-edgar","filing":"0001415889-25-023700","document":"form4-09042025_050901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023700/form4-09042025_050901.xml","form_type":"4"}},{"id":1551109,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:27.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":263960,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":2149418,"source":{"system":"sec-edgar","filing":"0001415889-24-010099","document":"form4-04032024_050412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924010099/form4-04032024_050412.xml","form_type":"4"}},{"id":1757071,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-10-20T10:50:07.000Z","date":"2023-10-19","kind":"purchase","planned":false,"acquired":true,"shares":16129,"price":1.41,"value":22741.89,"ownership":{"direct":true},"balance_after":132516,"source":{"system":"sec-edgar","filing":"0001415889-23-014454","document":"form4-10202023_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923014454/form4-10202023_061001.xml","form_type":"4"}},{"id":1757070,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-10-20T10:50:07.000Z","date":"2023-10-19","kind":"purchase","planned":false,"acquired":true,"shares":48387,"price":1.4,"value":67741.8,"ownership":{"direct":true},"balance_after":116387,"source":{"system":"sec-edgar","filing":"0001415889-23-014454","document":"form4-10202023_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923014454/form4-10202023_061001.xml","form_type":"4"}},{"id":1804395,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:58.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":800000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":1885458,"source":{"system":"sec-edgar","filing":"0001104659-23-093073","document":"tm2324046-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093073/tm2324046-4_4seq1.xml","form_type":"4"}},{"id":2162618,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:02:43.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029."}],"balance_after":750000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001104659-22-098949","document":"tm2225460-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098949/tm2225460-6_4seq1.xml","form_type":"4"}},{"id":2297952,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-13T20:05:46.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":68000,"price":1.5,"value":102000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person holds the shares in an account with his spouse as joint tenants."}],"balance_after":68000,"source":{"system":"sec-edgar","filing":"0001104659-22-045488","document":"tm2212654-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922045488/tm2212654-1_4seq1.xml","form_type":"4"}},{"id":2369933,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-28T22:01:13.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":637531,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":1085458,"source":{"system":"sec-edgar","filing":"0001104659-22-028157","document":"tm227910-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922028157/tm227910-1_4seq1.xml","form_type":"4"}},{"id":3057694,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-14T21:01:00.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":447927,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":447927,"source":{"system":"sec-edgar","filing":"0001104659-20-095623","document":"tm2027654-1_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920095623/tm2027654-1_4a.xml","form_type":"4/A","original_submission_date":"2020-08-13"}},{"id":3059115,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-13T21:02:48.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":447927,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\").  Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest.  Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":447927,"source":{"system":"sec-edgar","filing":"0001104659-20-094753","document":"tm2027548d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094753/tm2027548d2_4.xml","form_type":"4"}},{"id":3472379,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-07-02T21:56:38.000Z","date":"2019-06-30","kind":"grant","acquired":true,"shares":1600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":1600000,"derivative":{"exercise_price":0.469,"expiration_date":"2029-06-30","underlying":"Common Stock","underlying_shares":1600000},"source":{"system":"sec-edgar","filing":"0001144204-19-033654","document":"tv524753_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420419033654/tv524753_4.xml","form_type":"4"}}]}